Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 18:00:00 29/11/2024 GMT			5-day change	1st Jan Change
5.150 ^USD	-0.77%		+1.18%	+22.04%

11-06	Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	MT
11-06	Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M	11-06	MT
Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024	11-06
Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024	11-06	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	11-06	CI
HC Wainwright Starts Vanda Pharmaceuticals With Buy Rating, $18 Price Target	10-31	MT
Global markets live: InPost, Nvidia, Coty, Verizon, Apple...	10-15
Sector Update: Health Care Stocks Rise Late Afternoon	10-14	MT
Sector Update: Health Care Stocks Higher Monday Afternoon	10-14	MT
Vanda Pharmaceuticals Shares Rise; Cycle Pharmaceuticals' Buyout Offer Rejected Again	10-14	MT
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer	10-14	RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.	10-13	CI
Vanda Pharma Shares Fall 15% as FDA Denies Approval of Tradipitant NDA for Treating Gastroparesis Symptoms	09-19	MT
U.S. FDA declines to approve Vanda's stomach paralysis drug	09-19	RE
Top Premarket Decliners	09-19	MT
FDA Rejects Vanda Pharma's Application for Gastroparesis Drug Tradipitant	09-19	DJ
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis	09-19	CI
FDA Decision Due on Vanda Pharma's Gastroparesis Drug	09-18	DJ
Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024	07-31
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M	07-31	MT
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024	07-31	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-31	CI
Cantor Fitzgerald Initiates Vanda Pharmaceuticals at Overweight With $11 Price Target	07-11	MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz	07-01	MT
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index	06-30	CI
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index	06-30	CI

Chart Vanda Pharmaceuticals Inc.

Duration

Period

VNDA: Dynamic Chart

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

203

Sector

Biotechnology & Medical Research

Calendar

04/02/2025 - Q4 2024 Earnings Release (Projected)

More about the company